As of August 2026, one of the most significant materials science breakthroughs in decades is moving from laboratory benchtop to clinical trial. A team at the University of Nottingham's School of Pharmacy and Department of Chemical and Environmental Engineering has created a bioinspired gel that can regrow human tooth enamel — the hardest substance in the body and, until now, one that could never be replaced once lost. The findings, published in Nature Communications, represent a potential paradigm shift for preventive and restorative dentistry worldwide, including in Canadian practices already contending with rising demand for minimally invasive care.
What Makes This Different from Fluoride Varnish or Remineralization Treatments
Dental professionals in Ontario and across Canada are already familiar with fluoride varnishes, calcium phosphate pastes, and hydroxyapatite toothpastes — products that strengthen existing enamel or slow demineralization. These treatments work on enamel that is still present but weakened. They cannot rebuild enamel that has been physically lost to erosion, abrasion, or caries.
The Nottingham gel operates on a fundamentally different mechanism. Rather than depositing a protective coating, it initiates epitaxial mineralization — a process where new hydroxyapatite crystals grow in alignment with the existing tooth structure, effectively extending the crystalline lattice of natural enamel. The result is not a patch or a sealant but new enamel tissue that is structurally continuous with the original tooth.
Pro Tip: If your practice currently uses fluoride varnishes or MI Paste for early-stage carious lesions, track this research closely. The clinical indications may initially overlap with your current remineralization protocols, but the mechanism — and potentially the outcomes — differ substantially.
How the Gel Works: Elastin-Like Recombinamers and Saliva-Driven Crystallization
The gel's active component is a class of engineered proteins called elastin-like recombinamers (ELRs). These synthetic proteins are designed to mimic the amelogenin and ameloblastin molecules that guide enamel formation during tooth development in childhood. In adults, these natural proteins are no longer produced — which is why enamel loss has historically been permanent.
When applied to a damaged tooth surface, the ELR gel forms a structured scaffold at the molecular level. This scaffold penetrates microscopic cracks and pores in the enamel surface, then recruits calcium and phosphate ions from the patient's own saliva to drive controlled crystal growth. According to Dr. Abshar Hasan, one of the lead researchers, "The material promotes growth of crystals in an integrated and organized manner, recovering the architecture of our natural healthy enamel."
Laboratory Results: What the Data Actually Shows
The research team tested the gel on 32 demineralized human molars under controlled laboratory conditions. Within two weeks, treated teeth developed densely packed enamel crystals — up to 10 micrometres thick — on previously eroded surfaces. The regenerated enamel demonstrated mechanical properties comparable to healthy natural tooth enamel, including resistance to simulated brushing forces, occlusal loading, and acidic environments.
These are promising results, but Canadian dental professionals should interpret them with appropriate clinical context. Ten micrometres is a thin layer — approximately one-tenth the thickness of a human hair. Whether repeated applications can build clinically meaningful enamel thickness, and whether this holds up under the complex oral environment over months and years, remains to be demonstrated in human trials.
Clinical Trial Timeline and Regulatory Path
The startup company Mintech-Bio, spun out of the University of Nottingham, is advancing the gel toward human clinical trials beginning in 2026. Formal safety data from these trials will be required before any regulatory authority — including Health Canada — can certify the product for widespread clinical use.
For Canadian dental professionals, the regulatory pathway would involve Health Canada's Medical Devices Bureau or the Natural and Non-prescription Health Products Directorate, depending on how the final product is classified. The timeline from first human trial to commercial availability in Canada is difficult to predict. Dental materials typically require several years of clinical data before regulatory submission, and Health Canada's review process adds additional time beyond that.
Pro Tip: Do not advise patients that enamel regeneration treatments are "coming soon" based on this research alone. Laboratory success does not guarantee clinical efficacy. However, this is worth tracking in your continuing education portfolio — the Royal College of Dental Surgeons of Ontario (RCDSO) expects practitioners to stay current with emerging evidence that may affect standard of care.
What This Could Mean for Canadian Dental Practices
If the clinical trials validate the laboratory findings and the product receives regulatory approval, the implications for dental practice in Ontario and across Canada would be substantial.
Preventive Care Could Expand Significantly
Currently, once enamel is lost, the treatment is restorative — composite fillings, inlays, onlays, or crowns. A product that can rebuild enamel could create an entirely new treatment category between "watch and remineralize" and "drill and fill." For practices in the Greater Toronto Area and across Ontario that already emphasize preventive care, this could represent both a clinical advance and a new revenue stream.
Early-Stage Caries Management May Change
The concept of "biological management" of early caries — arresting and reversing the disease process rather than surgically removing affected tissue — has been gaining traction in Canadian dental education, including at the University of Toronto Faculty of Dentistry. An enamel regeneration product would be the most powerful tool in that approach, potentially reducing the number of restorations placed for early lesions.
Erosion Treatment Could Become Proactive
Dental erosion from acidic diets, gastroesophageal reflux, and eating disorders is a growing concern in Canadian dental practices, particularly among younger patients. Currently, management is largely reactive — sensitivity treatment, bonding, and eventual crowns. A regenerative approach could intervene much earlier in the erosion continuum.
The Broader Materials Science Context
This research sits within a larger trend in dental materials science toward bioactive and biomimetic approaches. Bioactive composites that release calcium and phosphate ions are already entering clinical use, and bioactive glass formulations are used in some desensitizing products. The Nottingham gel goes further by not just releasing ions but actively directing crystal growth — a distinction that, if it translates clinically, would represent a qualitative leap in the field.
Canadian dental professionals should also be aware that several other research groups globally are pursuing enamel regeneration through different mechanisms, including peptide-based approaches and hydroxyapatite nanoparticle technologies. The Nottingham ELR gel is currently the most advanced in terms of published data and clinical trial readiness, but the field is active and competitive.
What Canadian Dentists Should Do Now
This is a research development to monitor, not a product to purchase or a protocol to implement. The appropriate professional responses at this stage include:
- Track the clinical trial results as they are published. The Nature Communications paper (DOI: 10.1038/s41467-025-64982-y) is the primary source; watch for follow-up publications from the Nottingham group and Mintech-Bio.
- Discuss with colleagues through your local dental study club, Ontario Dental Association (ODA) chapter events, or continuing education programs. Understanding the science now will help you evaluate the clinical evidence when it arrives.
- Brief your patients appropriately if they ask. Patients may see media coverage of this research. Accurate, measured information from their dentist is more valuable than sensationalized headlines.
- Continue current best practices for enamel preservation: fluoride protocols, dietary counselling, and early intervention for erosive conditions. These remain the standard of care regardless of what future products may offer.
Pro Tip: Bookmark the ClinicalTrials.gov registry and search for "enamel regeneration" or "Mintech-Bio" periodically. Clinical trial registrations will appear there before results are published, giving you an early signal on study design, endpoints, and timeline.
Frequently Asked Questions
Q: Can the enamel regeneration gel replace dental fillings?
Not yet, and possibly not for significant cavities even if approved. The laboratory data shows regrowth of up to 10 micrometres of enamel — sufficient for early-stage erosion or white-spot lesions, but orders of magnitude thinner than what would be needed to replace a composite restoration in a cavitated tooth. The initial clinical applications, if approved, would likely target early demineralization and erosion rather than replacing existing restorative techniques.
Q: When will this gel be available in Canadian dental offices?
Human clinical trials are beginning in 2026, but regulatory approval and commercial availability in Canada are likely several years away at minimum. Health Canada would need to review clinical safety and efficacy data before authorizing the product for use. Canadian dentists should not expect to stock this product in the near term.
Q: Is fluoride still necessary if enamel can be regrown?
Yes. Fluoride's role in caries prevention extends beyond enamel strengthening — it inhibits bacterial acid production, promotes remineralization of subsurface lesions, and integrates into the crystal lattice to make enamel more acid-resistant. Even if enamel regeneration becomes clinically available, fluoride-based preventive protocols would remain a cornerstone of dental caries management. The two approaches would be complementary, not competitive.
EBIKO Dental will continue monitoring this research and reporting on developments relevant to Canadian dental professionals. For the latest industry news and clinical updates, visit ebiko.ca.